Trial Profile

Basket Study of Brigatinib in Patients with Advanced Solid Tumors with ROS1 Rearrangement

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brigatinib (Primary)
Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer; Solid tumours
Focus Therapeutic Use
Acronyms Barossa study
Sponsors Takeda Pharma

Most Recent Events

13 Sep 2022 Primary endpoint has been met (objective response rate) , Results presented at the 47th European Society for Medical Oncology Congress
13 Sep 2022 Results (n=28) reporting efficacy and data from cohort 1 of this trial in which TKI-naive ROS1-rearranged NSCLC patients were enrolled presented at the 47th European Society for Medical Oncology Congress
14 Sep 2021 Results (n=19) of cohort 2 were presented at the 2021 World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com